

Imugene Limited
 (ASX: IMU)

RESULTS OF GENERAL MEETING – Oncolytic Virus Acquisition Complete
Monday, 18th November 2019

The Company wishes to advise that all resolutions were carried unanimously on show of hands.

In accordance with Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the General Meeting held today.

Resolutions		For Votes	Against Votes	Proxy's Discretionary Votes*	Exclusions	Abstain	Carried / Not Carried
1	Approval of allotment and issue of Consideration Shares to unrelated Vaxinia Shareholders	1,156,258,075	12,171,931	22,206,851	-	2,544,401	Carried
2	Approval of allotment and issue of Consideration Shares to related parties: Paul Hopper and persons and entities related to him	1,142,861,885	19,254,823	22,588,000	-	8,476,550	Carried
3	Approval of acquisition of Vaxinia Pty Ltd, a related party of Imugene	1,156,891,627	10,109,203	22,974,180	-	3,206,248	Carried

* The Chairman voted undirected proxies in his control in favour of all resolutions.

Imugene's MD and CEO, Ms Leslie Chong said "we are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence of such a promising next generation oncolytic virus in a competitive market place where big pharma companies are actively seeking OV technologies. CF33 comes with robust intellectual property and long patent life, compelling pre-clinical efficacy and safety, and is anticipated to enter two Phase 1 clinical trials in 2020."

On behalf of the Board



 Phillip Hains
 Company Secretary